Surprisingly, NK cells, when unhinged from NKG2A masking, might not only enhance their natural cytotoxicity, but also improve their capacity to destroy tumor cells when tumor antigen-specific therapeutic antibodies are used, via their potent CD16-mediated ADCC activity. Here, KLRC1 is linked to neoplasm.